Laryngeal Cryotherapy for Refractory Neurogenic Cough
United States28 participantsStarted 2022-12-26
Plain-language summary
This study aims to evaluate the safety and efficacy of upper aerodigestive tract cryotherapy treatment in patients with refractory neurogenic cough in a prospective pilot study with a validated patient reported outcome measure
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult patients 18 years or older with diagnosis of neurogenic cough
* Neurogenic cough is a diagnosis of exclusion applied to persistent cough (8 weeks or longer)
* Negative workup for other causes, including sinonasal allergies/chronic sinusitis, cough-variant asthma, and GERD
* Patient willing to participate in a clinical trial
Exclusion Criteria:
* Uncontrolled reflux (scoring on Reflux Symptom index of 13 or higher)
* Vocal fold abnormalities or impairment
* History of asthma or other underlying lung condition not adequately treated or controlled
* Uncontrolled Allergic Rhinitis (Total Nasal Symptom Score \>6, which would indicate moderate disease32)
* Reported symptom of postnasal drip
* Current smoker
* Current neuromodulator medication use
* Patient unwilling to participate in clinical trial or sign an informed consent
* End stage medical disease with poor life expectancy
* Medical instability deemed by the investigators as a contraindication for enrollment
* Abnormal Chest X-ray
* Abnormal pulmonary function testing (PFTs)
* Positive local allergy panel (combined RAST testing)
What they're measuring
1
Improved quality of life of patients suffering from chronic cough
Timeframe: 2 years
2
Pre and Post-time point differences.
Timeframe: 2 years
Trial details
NCT IDNCT05665244
SponsorUniversity of Texas Southwestern Medical Center